Dr Mayoni Gooneratne examines systemic peptide use in longevity and wellness practice Peptide-based drugs have moved rapidly from niche therapeutics to a major growth area across endocrine, metabolic, oncologic and rare disease medicine.¹⁻⁴ At the same time, a parallel market …
Subscriber content
Continue reading this clinical article
To read this post in full you need an Aesthetics Journal subscription. Choose the plan that fits your practice — every paid plan includes the complete peer-reviewed clinical library and CPD-accredited learning.
Already a subscriber? Log in
